Trial Profile
A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Apr 2022
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors SymBio Pharmaceuticals
- 01 May 2022 Results published in the Annals of Hematology
- 29 Sep 2021 According to a SymBio Pharmaceuticals media release, results from this study were presented at the 83rd Annual Meeting of the Japanese Society of Hematology.
- 21 Jun 2020 Results (N=38) of safety and efficacy of bendamustine combined with rituximab presented at the 25th Congress of the European Haematology Association